延长持续时间血栓预防对急性内科住院患者静脉血栓栓塞和大出血的影响:双变量分析
该研究基于EXCLAIM、ADOPT、MAGELLAN和APEX四项随机对照试验共28227例急性内科住院患者数据,采用双变量方法同时评估延长(30-46天)与标准(6-14天)血栓预防对症状性VTE和大出血的影响。结果显示延长全剂量贝曲沙班在疗效上优于且安全性不劣于标准依诺肝素,双变量结局风险差为-0.51%。
要点
- 延长全剂量贝曲沙班(80mg每日一次)疗效优于标准依诺肝素,安全性不劣于后者
- 延长依诺肝素疗效优但安全性劣;阿哌沙班和利伐沙班疗效非劣但安全性劣
- 减量贝曲沙班在疗效和安全性上均未显示显著差异
核心结论
- 在假设非线性风险-获益权衡的双变量分析中,延长全剂量贝曲沙班预防优于标准持续时间依诺肝素,而其他方案未能同时达到症状性VTE的优效性和大出血的非劣效性。
研究设计与样本
- 基于四项随机对照试验(EXCLAIM、ADOPT、MAGELLAN和APEX)的28227例急性内科住院患者数据,采用不假设线性风险-获益权衡且可容纳不同疗效与安全性界值的双变量方法,同时评估延长(30-46天)与标准(6-14天)血栓预防对症状性VTE和大出血的影响。
主要发现
- 延长全剂量贝曲沙班(80mg每日一次)在疗效上优于且安全性不劣于标准持续时间依诺肝素,双变量结局风险差为-0.51%(-0.89%至-0.10%)。
- 延长依诺肝素疗效优但安全性劣,双变量结局为0.03%(-0.37%至0.43%)。
- 阿哌沙班和利伐沙班疗效非劣但安全性劣,双变量结局分别为-0.20%(-0.49%至0.17%)和0.23%(-0.16%至0.69%)。
- 减量贝曲沙班在疗效或安全性上均未显示显著差异,双变量结局为0.41%(-0.85%至1.94%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Anticoagulants prevent venous thromboembolism but may be associated with greater bleeding risks. Bivariate analysis assumes a non-linear relationship between efficacy and safety outcomes. Extended full-dose betrixaban is favorable over standard enoxaparin in bivariate endpoint. Clinicians must weigh efficacy and safety outcomes in decision-making on thromboprophylaxis. SUMMARY: Background Among acutely ill hospitalized medical patients, extended-duration thromboprophylaxis reduces the risk of venous thromboembolism (VTE), but some pharmacologic strategies have been associated with greater risks of major bleeding, thereby offsetting the net clinical benefit (NCB). Methods To assess the risk-benefit profile of anticoagulation regimens, a previously described bivariate method that does not assume a linear risk-benefit tradeoff and can accommodate different margins for efficacy and safety was performed to simultaneously assess efficacy (symptomatic VTE) and safety (major bleeding) on the basis of data from four randomized controlled trials of extended-duration (30-46 days) versus standard-duration (6-14 days) thromboprophylaxis among 28 227 patients (EXCLAIM, ADOPT, MAGELLAN and APEX trials). Results Extended thromboprophylaxis with full-dose betrixaban (80 mg once daily) was superior in efficacy and non-inferior in safety to standard-duration enoxaparin, and showed a significantly favorable NCB, with a risk difference of - 0.51% (- 0.89% to - 0.10%) in the bivariate outcome. Extended enoxaparin was superior in efficacy and inferior in safety (bivariate outcome: 0.03% [- 0.37% to 0.43%]), whereas apixaban and rivaroxaban were non-inferior in efficacy and inferior in safety (- 0.20% [- 0.49% to 0.17%] and 0.23% [- 0.16% to 0.69%], respectively). Reduced-dose betrixaban did not show a significant difference in either efficacy or safety (0.41% [- 0.85% to 1.94%]). Conclusions In a bivariate analysis that assumes non-linear risk-benefit tradeoffs, extended prophylaxis with full-dose betrixaban was superior to standard-duration enoxaparin, whereas other regimens failed to simultaneously achieve both superiority and non-inferiority with respect to symptomatic VTE and major bleeding in the management of acutely ill hospitalized medical patients.
引用
- Chi G, Goldhaber SZ, Kittelson JM, et al. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017. PMID: 28762617. doi:10.1111/jth.13783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。